Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Wickes H1 revenues grow, retail sales 'strong'

(Sharecast News) - Home improvement retailer Wickes said on Thursday that interim revenues had grown on the back of a "strong" retail sales growth and a return to positive like-for-like trading in its design and installation arm in Q2. Wickes said overall group revenue increased 5.6% year-on-year to £847.9m, with retail sales continuing to perform well, with revenues up 6.8% at £634.4m. In design and installation, a return to LFL sales growth in Q2 resulted in H1 revenues improving by 2.1% year-on-year to £213.4m.

"This has been a period of strong sales growth for Retail, driven by an increase in volumes while pricing remained broadly stable," said Wickes.

"In particular, we successfully fulfilled strong customer demand across timber, garden maintenance and decorating, which saw us further increase our market share during the half to record levels."

Wickes also noted that its balance sheet remains strong, with net cash of £158.0m at the half, after having used £8.1m as part of its ongoing £20.0m share buyback programme and £11.9m in share purchases made for the Employee Benefit Trust.

"The actions we have taken to invest in our growth levers and digital initiatives have set us up well for a successful 2025. While the business continues to face into the significant cost headwinds seen across the retail sector, our ongoing productivity programme and the strong first half performance means that we remain comfortable with current consensus expectations for adjusted PBT in 2025," added Wickes.

As of 1030 BST, Wickes shares were up 5.22% at 232.00p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.